Lyra Therapeutics Reports Topline Results from Phase 3

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE...

Related Keywords

United States ,Ellen Cavaleri ,Maria Palasis ,Linkedin ,Company Phase ,Lyra Therapeutics Inc ,Nasdaq ,While The Company ,Company Quarterly Report On Form ,Chief Executive Officer ,Sino Nasal Outcome Test ,Lyra Therapeutics ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,Nasdaq Lyra ,